Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Surmodics, Inc. - Common Stock (NQ:SRDX)

27.88 +0.45 (+1.64%)
Streaming Delayed Price Updated: 10:13 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Surmodics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3
From Surmodics, Inc.
Via Business Wire
Surmodics Announces Results from Sex-Specific Analysis of the PROWL Registry Study of Real-World Limb Ischemia Patients Treated with the Pounce™ Thrombectomy Platform
From Surmodics, Inc.
Via Business Wire
Surmodics Announces PROWL Registry Sex-Specific Data to be Presented at TCT Conference on October 28
From Surmodics, Inc.
Via Business Wire
What's Next: Surmodics's Earnings Preview
 
Via Benzinga
Earnings Scheduled For April 30, 2025
 
Via Benzinga
A Look at Surmodics's Upcoming Earnings Report
 
Via Benzinga
Surmodics Inc (NASDAQ:SRDX) Beats Q3 Earnings Estimates Despite Revenue Challenges, Raises Full-Year Guidance
Surmodics Inc (SRDX) beats Q3 earnings estimates with $0.06 EPS, raises FY2025 guidance. Revenue dips 3% but Pounce Thrombectomy grows 35%. Shares rise on improved profitability. 
Via Chartmill
Surmodics (SRDX) Q3 EPS Turns Positive
Via The Motley Fool
Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Earnings Scheduled For August 8, 2025
 
Via Benzinga
Top 3 Health Care Stocks You'll Regret Missing This Month
 
Via Benzinga
Surmodics to Report Third Quarter of Fiscal 2025 Financial Results on August 8
From Surmodics, Inc.
Via Business Wire
9 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30
From Surmodics, Inc.
Via Business Wire
Surmodics Earnings Analysis: Q1 Recap
 
Via Benzinga
Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon
From Surmodics, Inc.
Via Business Wire
Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries
From Surmodics, Inc.
Via Business Wire
Deal Dispatch: Clock Ticks On TikTok, Raizen Explores Asset Sale, Investors Urge Walgreens To Go Private
This week's Deal Dispatch has updates on Raizen, Walgreens, TikTok and Canoo. Plus: the FTC is blocking mergers like it's 2017 again. 
Via Benzinga
Why Surmodics Stock Is Falling On Friday
Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR. 
Via Benzinga
Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR
From Surmodics, Inc.
Via Business Wire
Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries
From Surmodics, Inc.
Via Business Wire
Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results
From Surmodics, Inc.
Via Business Wire
Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results
From Surmodics, Inc.
Via Business Wire
Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System
From Surmodics, Inc.
Via Business Wire
Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter
From Surmodics, Inc.
Via Business Wire
SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q3 2024
SRDX stock results show that Surmodics beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2024. 
Via InvestorPlace
Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results
From Surmodics, Inc.
Via Business Wire
SURMODICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, SRDX, AGS, VAPO on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.